News

Castle Biosciences to Present at the KeyBanc Capital Markets Virtual Life Sciences & MedTech Investor Forum

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CastleBiosciences--Castle Biosciences' executive management will present a company overview at the KeyBanc Capital Markets Virtual Life Sciences & MedTech Investor Forum.

03/12/2024

Castle Biosciences to Present New Data Highlighting the Clinical Value of its Dermatologic Tests for Patients with Skin Cancer at the 2024 American Academy of Dermatology (AAD) Annual Meeting

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #AAD2024--Castle Biosciences announces it will share data across its dermatologic portfolio of gene expression profile tests at the 2024 AAD Annual Meeting.

03/08/2024

Profitability

Dividends

Income Statement

Balance Sheet

Cash Flow Statement

Symbol Frequently Asked Questions

Is Castle Biosciences, Inc. (CSTL) a buy, sell, or hold?

Castle Biosciences, Inc. (CSTL) can hold. Click on Rating Page for detail.

What is Castle Biosciences, Inc.'s stock price?

The price of Castle Biosciences, Inc. (CSTL) is 19.31 and it was updated on 2024-04-20 01:36:42.

Is Castle Biosciences, Inc. (CSTL) overvalued or undervalued?

Currently Castle Biosciences, Inc. (CSTL) is in undervalued.

News

From:

To:

News
Castle Biosciences, Inc. (CSTL) Q4 2023 Earnings Call Transcript Castle Biosciences, Inc. (CSTL) Q4 2023 Earnings Call Transcript Wed, Feb. 28, 2024
Castle Biosciences, Inc. (CSTL) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates The headline numbers for Castle Biosciences, Inc. (CSTL) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals. Wed, Feb. 28, 2024
Castle Biosciences, Inc. (CSTL) Reports Q4 Loss, Tops Revenue Estimates Castle Biosciences, Inc. (CSTL) came out with a quarterly loss of $0.10 per share versus the Zacks Consensus Estimate of a loss of $0.84. This compares to loss of $0.78 per share a year ago. Wed, Feb. 28, 2024
Castle Biosciences to Present at Upcoming Investor Conferences FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CastleBiosciences--Castle Biosciences' executive management will present a company overview at three investor conferences later this month. Wed, Nov. 08, 2023
Here's What Key Metrics Tell Us About Castle Biosciences, Inc. (CSTL) Q3 Earnings Although the revenue and EPS for Castle Biosciences, Inc. (CSTL) give a sense of how its business performed in the quarter ended September 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers. Thu, Nov. 02, 2023

Transcripts

Transcipts Data
Castle Biosciences, Inc. (CSTL) on Q3 2023 Results - Earnings Call Transcript SA Transcripts Fri, Nov. 03, 2023
Castle Biosciences, Inc. (CSTL) on Q2 2023 Results - Earnings Call Transcript SA Transcripts Wed, Aug. 02, 2023
Castle Biosciences, Inc. (CSTL) on Q1 2023 Results - Earnings Call Transcript SA Transcripts Wed, May. 03, 2023
Castle Biosciences, Inc. (CSTL) on Q4 2022 Results - Earnings Call Transcript SA Transcripts Fri, Mar. 03, 2023
Castle Biosciences, Inc. (CSTL) on Q3 2022 Results - Earnings Call Transcript SA Transcripts Thu, Nov. 03, 2022
Castle Biosciences, Inc. (CSTL) on Q2 2022 Results - Earnings Call Transcript SA Transcripts Fri, Aug. 12, 2022
Castle Biosciences, Inc. (CSTL) on Q1 2022 Results - Earnings Call Transcript SA Transcripts Mon, May. 09, 2022
Castle Biosciences, Inc. (CSTL) on Q4 2021 Results - Earnings Call Transcript SA Transcripts Mon, Feb. 28, 2022
Castle Biosciences, Inc. (CSTL) on Q3 2021 Results - Earnings Call Transcript SA Transcripts Mon, Nov. 08, 2021
Castle Biosciences, Inc. (CSTL) on Q2 2021 Results - Earnings Call Transcript SA Transcripts Wed, Aug. 11, 2021
Castle Biosciences, Inc. (CSTL) on Q1 2021 Results - Earnings Call Transcript SA Transcripts Mon, May. 10, 2021

SEC Filings

SEC Filings
Castle Biosciences, Inc. (CSTL) - EFFECT SEC Filings 04/17/2024
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 04/16/2024
Castle Biosciences, Inc. (CSTL) - DEFA14A SEC Filings 04/10/2024
Castle Biosciences, Inc. (CSTL) - DEF 14A SEC Filings 04/10/2024
Castle Biosciences, Inc. (CSTL) - ARS SEC Filings 04/10/2024
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 04/10/2024
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 04/08/2024
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 04/05/2024
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 03/28/2024
Castle Biosciences, Inc. (CSTL) - 3 SEC Filings 03/28/2024
Castle Biosciences, Inc. (CSTL) - 8-K - Current report SEC Filings 03/27/2024
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 03/22/2024
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 03/11/2024
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 03/06/2024
Castle Biosciences, Inc. (CSTL) - S-8 SEC Filings 02/28/2024
Castle Biosciences, Inc. (CSTL) - S-3 SEC Filings 02/28/2024
Castle Biosciences, Inc. (CSTL) - 8-K - Current report SEC Filings 02/28/2024
Castle Biosciences, Inc. (CSTL) - 10-K - Current report SEC Filings 02/28/2024
Castle Biosciences, Inc. (CSTL) - SC 13G SEC Filings 02/14/2024
Castle Biosciences, Inc. (CSTL) - SC 13G SEC Filings 02/13/2024
Castle Biosciences, Inc. (CSTL) - SC 13G/A SEC Filings 02/09/2024
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 02/09/2024
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 02/07/2024
Castle Biosciences, Inc. (CSTL) - SC 13G/A SEC Filings 01/25/2024
Castle Biosciences, Inc. (CSTL) - 8-K - Current report SEC Filings 01/08/2024
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 01/08/2024
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 01/04/2024
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 01/03/2024
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 12/29/2023
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 12/27/2023
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 12/22/2023
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 12/20/2023
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 12/18/2023
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 12/14/2023
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 12/12/2023
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 12/08/2023
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 12/05/2023
Castle Biosciences, Inc. (CSTL) - S-8 SEC Filings 12/04/2023
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 12/01/2023
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 11/28/2023
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 11/22/2023
Castle Biosciences, Inc. (CSTL) - 8-K - Current report SEC Filings 11/09/2023
Castle Biosciences, Inc. (CSTL) - 8-K - Current report SEC Filings 11/02/2023
Castle Biosciences, Inc. (CSTL) - 10-Q - Quarterly Report SEC Filings 11/02/2023
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 09/06/2023
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 09/01/2023
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 08/07/2023
Castle Biosciences, Inc. (CSTL) - 8-K - Current report SEC Filings 08/02/2023
Castle Biosciences, Inc. (CSTL) - 10-Q - Quarterly Report SEC Filings 08/02/2023
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 07/18/2023
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 07/11/2023
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 06/06/2023
Castle Biosciences, Inc. (CSTL) - 8-K - Current report SEC Filings 06/05/2023
Castle Biosciences, Inc. (CSTL) - 8-K - Current report SEC Filings 06/01/2023
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 05/30/2023
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 05/17/2023
Castle Biosciences, Inc. (CSTL) - DEFA14A SEC Filings 05/15/2023
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 05/12/2023
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 05/08/2023
Castle Biosciences, Inc. (CSTL) - 8-K - Current report SEC Filings 05/03/2023
Castle Biosciences, Inc. (CSTL) - 10-Q - Quarterly Report SEC Filings 05/03/2023
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 04/14/2023
Castle Biosciences, Inc. (CSTL) - DEFA14A SEC Filings 04/12/2023
Castle Biosciences, Inc. (CSTL) - DEF 14A SEC Filings 04/12/2023
Castle Biosciences, Inc. (CSTL) - ARS SEC Filings 04/12/2023
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 04/06/2023
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 04/05/2023
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 03/16/2023
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 03/08/2023
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 03/06/2023
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 03/03/2023
Castle Biosciences, Inc. (CSTL) - S-8 SEC Filings 03/01/2023
Castle Biosciences, Inc. (CSTL) - S-8 SEC Filings 02/28/2023
Castle Biosciences, Inc. (CSTL) - 8-K - Current report SEC Filings 02/28/2023
Castle Biosciences, Inc. (CSTL) - 10-K - Current report SEC Filings 02/28/2023
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 02/14/2023
Castle Biosciences, Inc. (CSTL) - SC 13G/A SEC Filings 02/09/2023
Castle Biosciences, Inc. (CSTL) - SC 13G SEC Filings 02/09/2023
Castle Biosciences, Inc. (CSTL) - SC 13G/A SEC Filings 02/03/2023
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 02/03/2023
Castle Biosciences, Inc. (CSTL) - 4/A SEC Filings 01/27/2023
Castle Biosciences, Inc. (CSTL) - 8-K - Current report SEC Filings 01/20/2023
Castle Biosciences, Inc. (CSTL) - 8-K - Current report SEC Filings 01/09/2023
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 01/05/2023
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 12/30/2022
Castle Biosciences, Inc. (CSTL) - 8-K - Current report SEC Filings 12/28/2022
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 12/21/2022
Castle Biosciences, Inc. (CSTL) - 8-K - Current report SEC Filings 12/15/2022
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 12/13/2022
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 12/07/2022
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 12/05/2022
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 12/01/2022
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 11/23/2022
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 11/14/2022
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 11/09/2022
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 11/03/2022
Castle Biosciences, Inc. (CSTL) - 8-K - Current report SEC Filings 11/02/2022
Castle Biosciences, Inc. (CSTL) - 10-Q - Quarterly Report SEC Filings 11/02/2022
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 10/26/2022
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 10/12/2022
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 10/06/2022
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 10/05/2022
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 09/06/2022
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 08/31/2022
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 08/17/2022
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 08/09/2022
Castle Biosciences, Inc. (CSTL) - 8-K - Current report SEC Filings 08/08/2022
Castle Biosciences, Inc. (CSTL) - 10-Q - Quarterly Report SEC Filings 08/08/2022
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 08/05/2022
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 08/03/2022
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 07/18/2022
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 07/07/2022
Castle Biosciences, Inc. (CSTL) - 4/A SEC Filings 06/13/2022
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 06/13/2022
Castle Biosciences, Inc. (CSTL) - 8-K - Current report SEC Filings 06/08/2022
Castle Biosciences, Inc. (CSTL) - S-3ASR SEC Filings 06/06/2022
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 06/06/2022
Castle Biosciences, Inc. (CSTL) - S-3ASR SEC Filings 06/03/2022
Castle Biosciences, Inc. (CSTL) - 8-K - Current report SEC Filings 06/03/2022
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 05/16/2022
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 05/12/2022
Castle Biosciences, Inc. (CSTL) - 8-K - Current report SEC Filings 05/09/2022
Castle Biosciences, Inc. (CSTL) - 10-Q - Quarterly Report SEC Filings 05/09/2022
Castle Biosciences, Inc. (CSTL) - 8-K - Current report SEC Filings 05/02/2022
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 04/28/2022
Castle Biosciences, Inc. (CSTL) - DEFA14A SEC Filings 04/21/2022
Castle Biosciences, Inc. (CSTL) - DEF 14A SEC Filings 04/21/2022
Castle Biosciences, Inc. (CSTL) - 8-K - Current report SEC Filings 04/07/2022
Castle Biosciences, Inc. (CSTL) - 8-K - Current report SEC Filings 04/04/2022
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 03/31/2022
Castle Biosciences, Inc. (CSTL) - 8-K - Current report SEC Filings 03/17/2022
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 03/16/2022
Castle Biosciences, Inc. (CSTL) - S-8 SEC Filings 02/28/2022
Castle Biosciences, Inc. (CSTL) - 8-K - Current report SEC Filings 02/28/2022
Castle Biosciences, Inc. (CSTL) - 10-K - Current report SEC Filings 02/28/2022
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 02/24/2022
Castle Biosciences, Inc. (CSTL) - SC 13G/A SEC Filings 02/11/2022
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 02/11/2022
Castle Biosciences, Inc. (CSTL) - SC 13G/A SEC Filings 02/10/2022
Castle Biosciences, Inc. (CSTL) - SC 13G SEC Filings 02/04/2022
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 01/26/2022
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 01/24/2022
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 01/20/2022
Castle Biosciences, Inc. (CSTL) - S-3ASR SEC Filings 01/14/2022
Castle Biosciences, Inc. (CSTL) - 8-K/A - Current report SEC Filings 01/14/2022
Castle Biosciences, Inc. (CSTL) - 8-K - Current report SEC Filings 01/10/2022
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 01/06/2022
Castle Biosciences, Inc. (CSTL) - 8-K - Current report SEC Filings 01/05/2022
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 12/14/2021
Castle Biosciences, Inc. (CSTL) - 8-K - Current report SEC Filings 12/06/2021
Castle Biosciences, Inc. (CSTL) - 8-K - Current report SEC Filings 12/03/2021
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 11/17/2021
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 11/12/2021
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 11/10/2021
Castle Biosciences, Inc. (CSTL) - 8-K - Current report SEC Filings 11/08/2021
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 11/08/2021
Castle Biosciences, Inc. (CSTL) - 10-Q - Quarterly Report SEC Filings 11/08/2021
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 10/25/2021
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 10/21/2021
Castle Biosciences, Inc. (CSTL) - 8-K - Current report SEC Filings 10/19/2021
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 10/08/2021
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 10/06/2021
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 10/01/2021
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 09/30/2021
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 09/29/2021
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 09/23/2021
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 09/16/2021
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 09/15/2021
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 09/10/2021
Castle Biosciences, Inc. (CSTL) - 8-K - Current report SEC Filings 09/09/2021
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 09/07/2021
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 09/02/2021
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 08/31/2021
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 08/25/2021
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 08/19/2021
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 08/17/2021
Castle Biosciences, Inc. (CSTL) - 8-K - Current report SEC Filings 08/09/2021
Castle Biosciences, Inc. (CSTL) - 10-Q - Quarterly Report SEC Filings 08/09/2021
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 08/06/2021
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 08/03/2021
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 07/28/2021
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 07/23/2021
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 07/21/2021
Castle Biosciences, Inc. (CSTL) - 8-K - Current report SEC Filings 07/16/2021
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 07/16/2021
Castle Biosciences, Inc. (CSTL) - 3 SEC Filings 07/16/2021
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 07/12/2021
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 07/09/2021
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 06/28/2021
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 06/24/2021
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 06/21/2021
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 06/17/2021
Castle Biosciences, Inc. (CSTL) - 8-K - Current report SEC Filings 06/14/2021
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 06/14/2021
Castle Biosciences, Inc. (CSTL) - SC 13G/A SEC Filings 06/10/2021
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 06/10/2021
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 06/03/2021
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 06/01/2021
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 05/27/2021
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 05/24/2021
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 05/20/2021
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 05/14/2021
Castle Biosciences, Inc. (CSTL) - DEFA14A SEC Filings 05/13/2021
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 05/13/2021
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 05/12/2021
Castle Biosciences, Inc. (CSTL) - 3 SEC Filings 05/12/2021
Castle Biosciences, Inc. (CSTL) - 8-K - Current report SEC Filings 05/10/2021
Castle Biosciences, Inc. (CSTL) - 10-Q - Quarterly Report SEC Filings 05/10/2021
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 04/29/2021
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 04/28/2021
Castle Biosciences, Inc. (CSTL) - DEFA14A SEC Filings 04/27/2021
Castle Biosciences, Inc. (CSTL) - DEF 14A SEC Filings 04/27/2021
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 04/23/2021
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 04/19/2021
Castle Biosciences, Inc. (CSTL) - 3/A SEC Filings 04/16/2021
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 04/15/2021
Castle Biosciences, Inc. (CSTL) - 3/A SEC Filings 04/15/2021
Castle Biosciences, Inc. (CSTL) - 3 SEC Filings 04/15/2021
Castle Biosciences, Inc. (CSTL) - 8-K - Current report SEC Filings 04/09/2021
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 04/08/2021
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 04/07/2021
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 04/02/2021
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 03/31/2021
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 03/30/2021
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 03/26/2021
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 03/23/2021
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 03/22/2021
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 03/18/2021
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 03/15/2021
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 03/12/2021
Castle Biosciences, Inc. (CSTL) - S-8 SEC Filings 03/11/2021
Castle Biosciences, Inc. (CSTL) - 10-K - Current report SEC Filings 03/11/2021
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 03/10/2021
Castle Biosciences, Inc. (CSTL) - 8-K - Current report SEC Filings 03/08/2021
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 03/01/2021
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 02/26/2021
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 02/25/2021
Castle Biosciences, Inc. (CSTL) - SC 13G/A SEC Filings 02/17/2021
Castle Biosciences, Inc. (CSTL) - SC 13G/A SEC Filings 02/16/2021
Castle Biosciences, Inc. (CSTL) - SC 13G/A SEC Filings 02/12/2021
Castle Biosciences, Inc. (CSTL) - SC 13G SEC Filings 02/11/2021
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 02/11/2021
Castle Biosciences, Inc. (CSTL) - SC 13G SEC Filings 02/10/2021
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 02/10/2021
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 02/02/2021
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 01/29/2021
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 01/27/2021
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 01/19/2021
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 01/15/2021
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 01/14/2021
Castle Biosciences, Inc. (CSTL) - 8-K - Current report SEC Filings 01/13/2021
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 01/13/2021
Castle Biosciences, Inc. (CSTL) - 5 SEC Filings 01/11/2021
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 12/31/2020
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 12/30/2020
Castle Biosciences, Inc. (CSTL) - 8-K - Current report SEC Filings 12/22/2020
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 12/21/2020
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 12/18/2020
Castle Biosciences, Inc. (CSTL) - 8-K - Current report SEC Filings 12/16/2020
Castle Biosciences, Inc. (CSTL) - 424B5 SEC Filings 12/16/2020
Castle Biosciences, Inc. (CSTL) - S-3ASR SEC Filings 12/14/2020
Castle Biosciences, Inc. (CSTL) - 8-K - Current report SEC Filings 12/14/2020
Castle Biosciences, Inc. (CSTL) - 424B5 SEC Filings 12/14/2020
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 12/14/2020
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 12/11/2020
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 12/09/2020
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 12/04/2020
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 12/03/2020
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 11/24/2020
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 11/20/2020
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 11/18/2020
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 11/16/2020
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 11/12/2020
Castle Biosciences, Inc. (CSTL) - 8-K - Current report SEC Filings 11/09/2020
Castle Biosciences, Inc. (CSTL) - 10-Q - Quarterly Report SEC Filings 11/09/2020
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 11/06/2020
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 11/05/2020
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 10/30/2020
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 10/22/2020
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 10/15/2020
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 10/14/2020
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 10/13/2020
Castle Biosciences, Inc. (CSTL) - SC 13D/A SEC Filings 10/09/2020
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 10/08/2020
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 10/06/2020
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 10/05/2020
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 09/24/2020
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 09/18/2020
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 09/16/2020
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 09/14/2020
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 09/11/2020
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 09/10/2020
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 09/09/2020
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 09/08/2020
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 09/04/2020
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 09/03/2020
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 09/02/2020
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 08/31/2020
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 08/27/2020
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 08/25/2020
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 08/21/2020
Castle Biosciences, Inc. (CSTL) - 8-K - Current report SEC Filings 08/20/2020
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 08/20/2020
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 08/19/2020
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 08/14/2020
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 08/12/2020
Castle Biosciences, Inc. (CSTL) - 8-K - Current report SEC Filings 08/10/2020
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 08/10/2020
Castle Biosciences, Inc. (CSTL) - 10-Q - Quarterly Report SEC Filings 08/10/2020
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 08/07/2020
Castle Biosciences, Inc. (CSTL) - 4/A SEC Filings 07/28/2020
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 07/28/2020
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 07/23/2020
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 07/21/2020
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 07/16/2020
Castle Biosciences, Inc. (CSTL) - SC 13D/A SEC Filings 07/14/2020
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 07/13/2020
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 07/09/2020
Castle Biosciences, Inc. (CSTL) - 8-K - Current report SEC Filings 06/30/2020
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 06/26/2020
Castle Biosciences, Inc. (CSTL) - EFFECT SEC Filings 06/25/2020
Castle Biosciences, Inc. (CSTL) - POS EX SEC Filings 06/25/2020
Castle Biosciences, Inc. (CSTL) - 424B4 SEC Filings 06/25/2020
Castle Biosciences, Inc. (CSTL) - EFFECT SEC Filings 06/24/2020
Castle Biosciences, Inc. (CSTL) - SC 13D/A SEC Filings 06/24/2020
Castle Biosciences, Inc. (CSTL) - S-1MEF SEC Filings 06/24/2020
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 06/23/2020
Castle Biosciences, Inc. (CSTL) - S-1 SEC Filings 06/22/2020
Castle Biosciences, Inc. (CSTL) - CORRESP SEC Filings 06/22/2020
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 06/22/2020
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 06/19/2020
Castle Biosciences, Inc. (CSTL) - UPLOAD SEC Filings 06/17/2020
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 06/17/2020
Castle Biosciences, Inc. (CSTL) - DRS SEC Filings 06/12/2020
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 06/12/2020
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 06/10/2020
Castle Biosciences, Inc. (CSTL) - 8-K - Current report SEC Filings 06/09/2020
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 06/08/2020
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 06/05/2020
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 06/04/2020
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 06/03/2020
Castle Biosciences, Inc. (CSTL) - 8-K - Current report SEC Filings 06/02/2020
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 06/01/2020
Castle Biosciences, Inc. (CSTL) - 8-K - Current report SEC Filings 05/28/2020
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 05/28/2020
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 05/26/2020
Castle Biosciences, Inc. (CSTL) - DEFA14A SEC Filings 05/22/2020
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 05/22/2020
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 05/21/2020
Castle Biosciences, Inc. (CSTL) - 4/A SEC Filings 05/19/2020
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 05/19/2020
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 05/18/2020
Castle Biosciences, Inc. (CSTL) - SC 13D/A SEC Filings 05/14/2020
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 05/14/2020
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 05/12/2020
Castle Biosciences, Inc. (CSTL) - 8-K - Current report SEC Filings 05/11/2020
Castle Biosciences, Inc. (CSTL) - 10-Q - Quarterly Report SEC Filings 05/11/2020
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 05/04/2020
Castle Biosciences, Inc. (CSTL) - DEFA14A SEC Filings 04/23/2020
Castle Biosciences, Inc. (CSTL) - DEF 14A SEC Filings 04/23/2020
Castle Biosciences, Inc. (CSTL) - 8-K - Current report SEC Filings 04/15/2020
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 04/03/2020
Castle Biosciences, Inc. (CSTL) - 3 SEC Filings 04/03/2020
Castle Biosciences, Inc. (CSTL) - 8-K - Current report SEC Filings 04/01/2020
Castle Biosciences, Inc. (CSTL) - S-8 SEC Filings 03/10/2020
Castle Biosciences, Inc. (CSTL) - 8-K - Current report SEC Filings 03/10/2020
Castle Biosciences, Inc. (CSTL) - 10-K - Current report SEC Filings 03/10/2020
Castle Biosciences, Inc. (CSTL) - 8-K - Current report SEC Filings 03/05/2020
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 02/21/2020
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 02/18/2020
Castle Biosciences, Inc. (CSTL) - SC 13G SEC Filings 02/12/2020
Castle Biosciences, Inc. (CSTL) - SC 13G SEC Filings 02/11/2020
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 02/10/2020
Castle Biosciences, Inc. (CSTL) - SC 13G SEC Filings 02/05/2020
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 02/04/2020
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 01/30/2020
Castle Biosciences, Inc. (CSTL) - 8-K - Current report SEC Filings 01/09/2020
Castle Biosciences, Inc. (CSTL) - 8-K - Current report SEC Filings 12/19/2019
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 12/17/2019
Castle Biosciences, Inc. (CSTL) - 8-K - Current report SEC Filings 11/14/2019
Castle Biosciences, Inc. (CSTL) - 8-K - Current report SEC Filings 11/12/2019
Castle Biosciences, Inc. (CSTL) - 10-Q - Quarterly Report SEC Filings 11/12/2019
Castle Biosciences, Inc. (CSTL) - 8-K - Current report SEC Filings 09/03/2019
Castle Biosciences, Inc. (CSTL) - 10-Q - Quarterly Report SEC Filings 09/03/2019
Castle Biosciences, Inc. (CSTL) - SC 13D SEC Filings 08/05/2019
Castle Biosciences, Inc. (CSTL) - 4 SEC Filings 07/31/2019
Castle Biosciences, Inc. (CSTL) - D SEC Filings 07/30/2019
Castle Biosciences, Inc. (CSTL) - S-8 SEC Filings 07/29/2019
Castle Biosciences, Inc. (CSTL) - 8-K - Current report SEC Filings 07/29/2019
Castle Biosciences, Inc. (CSTL) - 424B4 SEC Filings 07/26/2019
Castle Biosciences, Inc. (CSTL) - 3/A SEC Filings 07/26/2019
Castle Biosciences, Inc. (CSTL) - EFFECT SEC Filings 07/25/2019
Castle Biosciences, Inc. (CSTL) - SEC STAFF LETTER SEC Filings 07/24/2019
Castle Biosciences, Inc. (CSTL) - S-1MEF SEC Filings 07/24/2019
Castle Biosciences, Inc. (CSTL) - 3 SEC Filings 07/24/2019
Castle Biosciences, Inc. (CSTL) - CORRESP SEC Filings 07/23/2019
Castle Biosciences, Inc. (CSTL) - CERT SEC Filings 07/23/2019
Castle Biosciences, Inc. (CSTL) - S-1/A SEC Filings 07/19/2019
Castle Biosciences, Inc. (CSTL) - FWP SEC Filings 07/19/2019
Castle Biosciences, Inc. (CSTL) - S-1/A SEC Filings 07/15/2019
Castle Biosciences, Inc. (CSTL) - CORRESP SEC Filings 07/15/2019
Castle Biosciences, Inc. (CSTL) - 8-A12B SEC Filings 07/15/2019
Castle Biosciences, Inc. (CSTL) - CORRESP SEC Filings 07/09/2019
Castle Biosciences, Inc. (CSTL) - UPLOAD SEC Filings 07/08/2019
Castle Biosciences, Inc. (CSTL) - S-1 SEC Filings 06/26/2019
Castle Biosciences, Inc. (CSTL) - CORRESP SEC Filings 06/26/2019
Castle Biosciences, Inc. (CSTL) - UPLOAD SEC Filings 06/10/2019
Castle Biosciences, Inc. (CSTL) - SEC STAFF LETTER SEC Filings 06/05/2019
Castle Biosciences, Inc. (CSTL) - DRS SEC Filings 05/14/2019
Castle Biosciences, Inc. (CSTL) - D/A SEC Filings 03/21/2019
Castle Biosciences, Inc. (CSTL) - D SEC Filings 02/14/2019
Castle Biosciences, Inc. (CSTL) - D SEC Filings 06/13/2018
Castle Biosciences, Inc. (CSTL) - D SEC Filings 01/19/2018
Castle Biosciences, Inc. (CSTL) - D SEC Filings 07/30/2015
Castle Biosciences, Inc. (CSTL) - D SEC Filings 08/18/2014
Castle Biosciences, Inc. (CSTL) - D SEC Filings 08/05/2014
Castle Biosciences, Inc. (CSTL) - D SEC Filings 05/05/2014
Castle Biosciences, Inc. (CSTL) - D SEC Filings 11/19/2013
Castle Biosciences, Inc. (CSTL) - D SEC Filings 05/16/2013
Castle Biosciences, Inc. (CSTL) - D SEC Filings 10/04/2012
Castle Biosciences, Inc. (CSTL) - D SEC Filings 03/12/2010
Castle Biosciences, Inc. (CSTL) - D/A SEC Filings 03/20/2009
Castle Biosciences, Inc. (CSTL) - REGDEX SEC Filings 10/02/2008

Press Releases

StockPrice Release
Castle biosciences to release first quarter 2024 financial results and host conference call on thursday, may 2, 2024 04/11/2024
Castle biosciences celebrates esophageal cancer awareness month through advocacy and educational collaborations 04/10/2024
Castle biosciences' chief financial officer frank stokes recognized as a top cfo of houston for second consecutive year 04/10/2024
Presentations at eado highlight potential impact of castle biosciences' decisiondx®-melanoma and decisiondx®-scc tests on the management of patients with skin cancer 04/04/2024
Castle biosciences to present at the 23rd annual needham virtual healthcare conference 04/02/2024
Castle biosciences announces updates to its board of directors 03/27/2024
Castle biosciences earns a top workplaces usa award for the third consecutive year 03/25/2024
Long-term outcomes data shared at sso 2024 show that patients with a low-risk decisiondx®-melanoma test result were recurrence free at three years, including those who utilized the test to help guide the decision to avoid an slnb 03/22/2024
Leading squamous cell carcinoma practitioners publish consensus guidelines integrating decisiondx®-scc into a clinical workflow to improve decision-making regarding the use of adjuvant radiation therapy 03/19/2024
New study shows that the drug-drug interactions and lifestyle factors provided by castle biosciences' idgenetix® test significantly improve medication recommendations over drug-gene interactions alone for patients 65 and older 03/15/2024
Castle biosciences to present at the keybanc capital markets virtual life sciences & medtech investor forum 03/12/2024
Castle biosciences to present new data highlighting the clinical value of its dermatologic tests for patients with skin cancer at the 2024 american academy of dermatology (aad) annual meeting 03/08/2024
In novel cohort, new data confirms decisiondx®-scc provides significant, independent and clinically actionable risk-stratification of patients, including in various high-risk subgroups 03/07/2024
Castle biosciences reports fourth quarter and full-year 2023 results 02/28/2024
Study finds decisiondx®-melanoma significantly improves the risk stratification of patients with stage i melanoma compared to american joint committee on cancer 8th edition staging 02/26/2024
Castle biosciences to release fourth quarter and full-year 2023 financial results and host conference call on wednesday, feb. 28, 2024 02/07/2024
New study highlights significant potential medicare savings through use of castle biosciences' decisiondx®-scc test to guide adjuvant radiation therapy decisions in patients with cutaneous squamous cell carcinoma 01/18/2024
Castle biosciences presents data supporting the utility of its tests in the clinical care of patients with skin cancers at the 2024 winter clinical dermatology conference - hawaii® 01/14/2024
Castle biosciences announces preliminary fourth quarter and full-year 2023 results 01/07/2024
Castle biosciences reports inducement grants under nasdaq listing rule 5635(c)(4) 12/20/2023
Study finds nurse practitioners and physician assistants would alter patient care decisions based on decisiondx®-melanoma test results 12/01/2023
Castle biosciences announces multiple data presentations at the 2023 american society for dermatologic surgery annual meeting 11/14/2023
Castle biosciences ranked among the top workplaces in houston by the houston chronicle for the third consecutive year 11/13/2023
Real-world evidence confirms idgenetix®-guided medication management significantly improves response and remission rates in patients with major depressive disorder 11/08/2023
Castle biosciences to present at upcoming investor conferences 11/08/2023
Castle announces early exploratory study data for potential development of a complementary test to accompany decisiondx®-um that could aid in the early detection of uveal melanomas 11/03/2023
Early discovery data shows ability of castle biosciences' pipeline program to distinguish between responders and non-responders to an atopic dermatitis therapy 11/02/2023
Castle biosciences to present new data on its tissuecypher® barrett's esophagus test at the 2023 american college of gastroenterology annual scientific meeting 10/24/2023
Castle biosciences to release third quarter 2023 financial results and host conference call on thursday, nov. 2 10/19/2023
New data highlights clinical utility and performance of castle biosciences' dermatologic test portfolio at the 2023 fall clinical dermatology conference® 10/18/2023
Decisiondx®-melanoma outperforms memorial sloan kettering cancer center (mskcc) nomogram in predicting sentinel lymph node positivity in patients with cutaneous melanoma 10/05/2023
Castle biosciences presents new data at astro 2023 highlighting risk-stratification performance of decisiondx®-scc in patients with cutaneous squamous cell carcinoma eligible for adjuvant radiation therapy 10/03/2023
Castle biosciences shares new data demonstrating ability of tissuecypher® test results to inform clinical decision-making in patients with non-dysplastic barrett's esophagus 10/02/2023
Castle biosciences, leading skin cancer expert, darrell rigel, m.d., m.s., and impact melanoma board member to ring nasdaq closing bell on sept. 09/25/2023
Castle biosciences ranked third among 2023 top workplaces in the healthcare industry 09/19/2023
Tissuecypher® barrett's esophagus test outperformed standard of care in risk-stratifying patients with barrett's esophagus 09/14/2023
Castle biosciences announces receipt of new york laboratory permit for pittsburgh laboratory 09/12/2023
Integrating drug-drug interactions and lifestyle factors with drug-gene interactions provided by castle biosciences' idgenetix® test significantly impacted the number of drug recommendations for patients with moderate to severe depression 09/09/2023
Tissuecypher® provides clinically-impactful risk stratification in patients with barrett's esophagus 09/08/2023
Castle biosciences to highlight clinical value of idgenetix® test at psych congress 2023 09/06/2023
Castle biosciences to participate in upcoming investor conferences 09/05/2023
New publication highlights the ability of the tissuecypher® barrett's esophagus test to improve and standardize the clinical management of low-grade dysplasia in patients with barrett's esophagus 08/07/2023
Castle biosciences reports second quarter 2023 results 08/02/2023
Castle biosciences to present at the canaccord genuity 43rd annual growth conference 08/01/2023
Castle biosciences to release second quarter 2023 financial results and host conference call on wednesday, aug. 2 07/19/2023
Castle biosciences to host second annual castle cares charity walk 07/18/2023
Castle biosciences honored as an arizona top workplace for the second consecutive year 07/17/2023
Investigation alert: the schall law firm announces it is investigating claims against castle biosciences, inc. and encourages investors with losses to contact the firm 07/17/2023
Investigation alert: the schall law firm announces it is investigating claims against castle biosciences, inc. and encourages investors with losses to contact the firm 07/12/2023
Castle biosciences to present new decisiondx®-scc and decisiondx®-melanoma data at the american head & neck society's (ahns) 11th international conference on head and neck cancer 07/07/2023
Investor action alert: the schall law firm announces it is investigating claims against castle biosciences, inc. and encourages investors with losses to contact the firm 07/07/2023
Shareholder action notice: the schall law firm announces it is investigating claims against castle biosciences, inc. and encourages investors with losses to contact the firm 07/03/2023
Study data from castle biosciences' collaboration with the national cancer institute's seer program registries published in jco precision oncology 06/30/2023
Investor action notice: the schall law firm announces it is investigating claims against castle biosciences, inc. and encourages investors with losses to contact the firm 06/26/2023
Investigation action alert: the schall law firm announces it is investigating claims against castle biosciences, inc. and encourages investors with losses to contact the firm 06/21/2023
Castle biosciences reports inducement grants under nasdaq listing rule 5635(c)(4) 06/20/2023
Investigation alert: the schall law firm announces it is investigating claims against castle biosciences, inc. and encourages investors with losses to contact the firm 06/17/2023
Kirby mcinerney llp continues investigation of shareholder claims against castle biosciences, inc. (cstl) 06/16/2023
Castle alert: bragar eagel & squire, p.c. is investigating castle biosciences, inc. on behalf of castle stockholders and encourages investors to contact the firm 06/15/2023
Shareholder action notice: the schall law firm announces it is investigating claims against castle biosciences, inc. and encourages investors with losses to contact the firm 06/13/2023
Castle biosciences presents new data demonstrating the ability of decisiondx®-scc to identify tumors likely to metastasize in patients with cutaneous squamous cell carcinoma deemed low risk by traditional staging 06/12/2023
Ongoing investigation alert: the schall law firm announces it is investigating claims against castle biosciences, inc. and encourages investors with losses to contact the firm 06/10/2023
Kirby mcinerney llp announces an investigation of shareholder claims against castle biosciences, inc. (cstl) 06/09/2023
Shareholder action alert: the schall law firm announces it is investigating claims against castle biosciences, inc. and encourages investors with losses to contact the firm 06/09/2023
Investigation reminder: the schall law firm announces it is investigating claims against castle biosciences, inc. and encourages investors with losses to contact the firm 06/06/2023
Ongoing investigation alert: the schall law firm announces it is investigating claims against castle biosciences, inc. and encourages investors with losses to contact the firm 06/06/2023
Investigation alert: the schall law firm announces it is investigating claims against castle biosciences, inc. and encourages investors with losses to contact the firm 06/05/2023
Framework incorporating decisiondx®-scc test results into clinical decision-making for patients with high-risk cutaneous squamous cell carcinoma published in clinical, cosmetic and investigational dermatology 06/05/2023
Castle biosciences to share new data on decisiondx®-melanoma and decisiondx®-um at the 2023 asco annual meeting 06/03/2023
Idgenetix® shown to significantly improve medication response and remission rates in patients with major depressive disorder 05/31/2023
Castle biosciences celebrates skin cancer awareness month 05/30/2023
Castle biosciences' abstracts at digestive disease week (ddw) annual meeting selected as “posters of distinction” by the american gastroenterological association (aga) institute council 05/26/2023
Castle biosciences opens new state-of-the-art laboratory in pittsburgh 05/22/2023
Castle biosciences' tissuecypher® barrett's esophagus test receives 2023 medtech breakthrough award for artificial intelligence innovation 05/15/2023
Castle biosciences reports first quarter 2023 results 05/03/2023
Study demonstrates use of decisiondx®-melanoma to guide treatment decisions resulted in earlier detection of melanoma with decreased metastatic tumor burden compared to patients without surveillance imaging studies 05/03/2023
Castle biosciences collaborates with impact melanoma to provide free sunscreen to cyclists participating in the bike ms: texas ms 150 2023 cycling event 04/28/2023
Decisiondx®-melanoma provides improved risk stratification over american joint committee on cancer (ajcc) staging alone in stage i melanoma patients 04/25/2023
Tissuecypher® test results can increase the likelihood of appropriate management decisions for barrett's esophagus patients with low-grade dysplasia 04/20/2023
Late-breaking data presented at the 2023 aad annual meeting demonstrates improved accuracy of decisiondx®-scc in predicting metastatic risk over traditional staging systems in independent, multi-center cohort study 03/18/2023
Castle biosciences to present at the keybanc capital markets virtual life sciences & medtech investor forum 03/14/2023
Castle biosciences to highlight clinical value of its skin cancer tests at the 2023 american academy of dermatology (aad) annual meeting 03/10/2023
Recommendations by expert consensus panel relating to risk-stratification tests and tools for use in cutaneous melanoma have been adopted as an official policy recommendation of the national society for cutaneous medicine 03/08/2023
Castle biosciences reports fourth quarter and full-year 2022 results 02/28/2023
Castle biosciences' chief financial officer frank stokes selected among the top 25 cfos of houston for 2023 by finance & investing 02/24/2023
Data presentation at 2023 winter clinical - miami™ highlights use of decisiondx®-melanoma to guide slnb surgery decisions in head and neck tumors 02/22/2023
Prospective, multicenter study demonstrates that decisiondx®-melanoma test results can significantly reduce the number of sentinel lymph node biopsy (slnb) procedures performed when used within the context of current guidelines 02/09/2023
Castle biosciences to release fourth quarter and full-year 2022 financial results and host conference call on tuesday, feb. 28, 2023 02/07/2023
Castle biosciences earns a top workplaces usa award for the second consecutive year 02/01/2023
Data presentations at 2023 winter clinical dermatology conference - hawaii® support clinical value of castle biosciences' skin cancer test portfolio 01/17/2023
Castle biosciences announces preliminary fourth quarter and full-year 2022 results 01/08/2023
Castle biosciences receives accreditation from the college of american pathologists for its pittsburgh clinical laboratory 11/21/2022
Research published in melanoma management finds that 99% of patients with uveal melanoma tested with decisiondx®-um gain value from the results 11/17/2022
Castle biosciences presents new data demonstrating the clinical utility and value of decisiondx®-scc in moderately and poorly differentiated cutaneous squamous cell carcinoma tumors 11/15/2022
Castle biosciences named a houston chronicle top workplace for the second consecutive year 11/14/2022
Castle biosciences announces third quarter 2022 results 11/02/2022
Real-world clinical utility study published in cancer investigation demonstrates the impact of decisiondx®-scc test results in guiding risk-aligned care for patients with cutaneous squamous cell carcinoma 10/31/2022
Castle biosciences presents new data from collaboration with the national cancer institute's (nci) surveillance, epidemiology and end results (seer) program 10/27/2022
New data demonstrate that the utilization of tissuecypher® barrett's esophagus test results can significantly improve the management of low-grade dysplasia in patients with barrett's esophagus over the standard of care alone 10/25/2022
Castle biosciences presents new data demonstrating the impact of decisiondx®-scc test results on the management of medicare-eligible patients with cutaneous squamous cell carcinoma and one or more risk factors 10/24/2022
New data from decide study show the significant role of decisiondx®-melanoma test results and patient preference in decisions to perform the sentinel lymph node biopsy (slnb) surgical procedure 10/20/2022
Castle biosciences to release third quarter 2022 financial results and host conference call on wednesday, nov. 2 10/19/2022
Results from a randomized controlled trial show that tissuecypher® barrett's esophagus test results can significantly improve the accuracy of risk assessments and adherence to guideline-recommended patient management 10/13/2022
Castle biosciences presents case study showcasing the diagnostic performance of diffdx®-melanoma at the college of american pathologists 2022 (cap22) annual meeting 10/11/2022
Castle biosciences to present data supporting the clinical value of its suite of skin cancer tests through multiple oral presentations at the 2022 american society for dermatologic surgery (asds) annual meeting 10/10/2022
Castle biosciences announces publication of study demonstrating the integration of decisiondx®-melanoma and clinicopathologic factors provides optimized, personalized survival prognoses for patients with cutaneous melanoma 09/23/2022
Castle biosciences presents clinical use scenarios for its diagnostic gene expression profile tests at maui derm np+pa fall 2022 conference 09/21/2022
Castle biosciences presents foundational guideposts and three-year financial targets at 2022 investor day 09/20/2022
Castle biosciences honored with a 2022 azbio fast lane award from the arizona bioindustry association 09/13/2022
Castle biosciences to participate in upcoming investor conferences 09/01/2022
Castle biosciences to host investor day on sept. 20, 2022 08/24/2022
Castle biosciences reports second quarter 2022 results 08/08/2022
American gastroenterological association (aga) clinical practice update states that tissuecypher® may be beneficial for risk-stratification of patients with non-dysplastic barrett's esophagus 08/04/2022
Castle biosciences to present at the canaccord genuity 42nd annual growth conference 08/03/2022
Castle biosciences to release second quarter 2022 financial results and host conference call on monday, august 8 07/25/2022
Decisiondx®-melanoma ordered more than 100,000 times for patients diagnosed with cutaneous melanoma 07/25/2022
Presentation at 2022 aad innovation academy to showcase the risk stratification of decisiondx®-melanoma and its role in the management of patients with cutaneous melanoma 07/20/2022
Castle biosciences honored with a 2022 arizona top workplace award 07/18/2022
Patients with uveal melanoma tested with decisiondx®-um report gaining value from test results in study conducted in collaboration with the melanoma research foundation's cure om initiative 06/23/2022
Castle adds to evidence supporting its skin cancer test portfolio through multiple data presentations at the sdpa annual summer dermatology conference 2022 06/22/2022
Castle biosciences announces support for ohsu's war on melanoma™ 06/20/2022
Collaborative study with melanoma research foundation confirms patients diagnosed with melanoma desire testing with decisiondx®-melanoma 06/14/2022
Castle biosciences' decisiondx®-melanoma test receives 2022 medtech breakthrough award 05/27/2022
Data demonstrating decisiondx®-melanoma's ability to risk-stratify patients according to melanoma-specific survival to be shared during the 2022 asco annual meeting 05/25/2022
Tissuecypher® outperforms pathologist diagnoses when predicting progression in patients diagnosed with barrett's esophagus with low-grade dysplasia 05/24/2022
Grant from research to prevent blindness and castle biosciences supports medical student research in ocular cancer 05/20/2022
Data from second independent multi-center study of patients with high-risk cutaneous squamous cell carcinoma confirms independent risk-stratification performance of decisiondx®-scc 05/19/2022
Castle biosciences collaborates with the sun bus to provide free skin cancer screenings 05/10/2022
Castle biosciences reports first quarter 2022 results 05/09/2022
Castle biosciences recognizes skin cancer awareness month through its support of patient-focused initiatives 05/03/2022
Castle biosciences announces expanded u.s. federal supply schedule contract covering its entire dermatologic cancer portfolio of tests 04/29/2022
Data from independent, pooled analysis show significantly improved risk predictions over clinical variables for tissuecypher® barrett's esophagus test and ability to identify patients at high risk of progressing to esophageal cancer 04/27/2022
Castle biosciences completes acquisition of altheadx 04/26/2022
Castle biosciences to release first quarter 2022 financial results and host conference call on monday, may 9 04/25/2022
Expanded seer registries dataset shows improved survival for decisiondx®-melanoma tested patients compared to untested patients 04/21/2022
Castle biosciences to present data at the 18th european association of dermato oncology (eado) congress 04/20/2022
Castle biosciences presents data on its inflammatory skin disease pipeline test at the 4th annual revolutionizing atopic dermatitis (rad) conference 04/18/2022
Castle biosciences to present at the 21st annual needham virtual healthcare conference 04/05/2022
Castle biosciences to acquire altheadx 04/04/2022
Castle biosciences receives advanced diagnostic laboratory test (adlt) status for tissuecypher® barrett's esophagus test from the centers for medicare & medicaid services (cms) 03/29/2022
Data to be presented at the 2022 american academy of dermatology (aad) annual meeting demonstrate ability of decisiondx®-melanoma and decisiondx®-scc to inform clinical decision making 03/25/2022
Independent data presented at society for surgical oncology conference demonstrated decisiondx®-melanoma outperforms t-stage at identifying patients with low risk of sentinel lymph node positivity 03/11/2022
Castle biosciences reports fourth quarter and full-year 2021 results 02/28/2022
Castle biosciences to release fourth quarter and full-year 2021 financial results and host conference call on monday, feb. 28, 2022 02/14/2022
Castle biosciences collaborates with the national cancer institute to link decisiondx®-melanoma testing data with seer registries' cutaneous melanoma cases 02/03/2022
Castle biosciences named a winner of the 2022 top workplaces usa award 02/02/2022
Recently published data confirm decisiondx®-scc as a significant and independent risk-stratification tool in patients with squamous cell carcinoma and one or more risk factors 01/13/2022
Data published in ocular oncology and pathology demonstrates highly accurate performance of decisiondx®-umseq for patients with uveal melanoma 01/12/2022
Castle biosciences to present at the 24th annual needham growth conference 12/28/2021
Castle biosciences presents data reinforcing the clinical utility of its decisiondx® dermatologic portfolio 11/24/2021
Data demonstrating decisiondx®-melanoma was a significant, independent predictor of metastatic recurrence in stage i-iii cutaneous melanoma published in future oncology 11/19/2021
Castle biosciences publishes decisiondx®-melanoma study on the validation of the i31-gep slnb artificial intelligence algorithm 11/05/2021
Castle biosciences' full decisiondx® portfolio of dermatologic tests to be interfaced with ema® electronic health records system 11/04/2021
New data demonstrating accuracy of decisiondx® diffdx™-melanoma presented at asdp 58th annual meeting 10/26/2021
Pittsburgh life sciences greenhouse proudly announces portfolio company cernostics is being acquired by castle biosciences 10/25/2021
Castle biosciences to release third quarter 2021 financial results and host conference call on monday, nov. 8, 2021 10/25/2021
Castle biosciences presents data from suite of dermatologic cancer genomic tests at fall clinical dermatology conference 2021 10/22/2021
Castle biosciences to acquire cernostics 10/19/2021
Castle biosciences president and ceo derek maetzold will deliver keynote presentation during arizona bioscience week 09/28/2021
Castle biosciences recognized as a top 100 healthcare technology company of 2021 08/30/2021
Castle biosciences awarded u.s. federal supply schedule contract for decisiondx-melanoma 08/24/2021
Castle biosciences to present data at the 2021 american academy of dermatology (aad) summer meeting 08/06/2021
Castle biosciences collaborates with the melanoma research foundation 08/02/2021
Castle biosciences to release second quarter 2021 financial results and host conference call on monday, aug. 9, 2021 07/26/2021
Castle biosciences presents new data demonstrating decisiondx®-scc complements current risk assessment methods in patients with cutaneous squamous cell carcinoma of the head and neck 07/23/2021
Castle biosciences presents data on decisiondx®-melanoma and decisiondx®-scc at sdpa annual summer dermatology conference 2021 07/22/2021
Castle biosciences expands its board of directors with new appointments 07/16/2021
Castle biosciences is listed in the houston chronicle's “chron 100” as one of the 100 most successful publicly traded companies in houston 06/21/2021
Castle biosciences to participate at the baird 2021 healthcare esg symposium 06/07/2021
Altheadx, inc. appoints industry veteran derek maetzold to its board of directors 05/26/2021
Castle biosciences to host ribbon cutting ceremony at new corporate headquarters 05/24/2021
Castle biosciences supports the american skin association with research grant 05/21/2021
Expert panel provides framework for incorporating decisiondx-scc results into clinical decision making for cutaneous squamous cell carcinoma patients with one or more risk factors 05/20/2021
Castle biosciences to participate in the oppenheimer medtech, tools, & diagnostics summit 05/19/2021
Castle biosciences announces first quarter 2021 results 05/10/2021
Castle biosciences supports american academy of dermatology's "skin cancer, take a hike!™" steps challenge for skin cancer awareness month 04/30/2021
Castle biosciences signs definitive agreement to acquire myriad mypath® laboratory 04/27/2021
Castle biosciences to release first quarter 2021 financial results, provide pipeline update and host conference call on monday, may 10, 2021 04/26/2021
Castle biosciences presents data demonstrating decisiondx-melanoma as significant, independent predictor of recurrence in stage i cutaneous melanoma population 04/23/2021
Castle biosciences presents data at the 10th world congress of melanoma and 17th european association of dermato-oncology congress 04/16/2021
Late-breaking new independent validation study of 1,674 patients demonstrates castle biosciences' i31-gep artificial intelligence algorithm improves precision of sentinel lymph node positivity prediction in cutaneous melanoma 04/15/2021
Largest, independent, prospective study demonstrates utility of decisiondx®-melanoma for prediction of outcomes in patients with cutaneous melanoma referred for sentinel node biopsy 04/14/2021
Castle biosciences announces prospective, multi-center publication demonstrating decisiondx®-melanoma as significant, independent predictor of patient outcomes in cutaneous melanoma 04/13/2021
Castle biosciences collaborates with the melanoma research foundation for “ask the expert” live webinar series with melanoma experts 04/01/2021
Castle biosciences to present at the 20th annual needham virtual healthcare conference 03/29/2021
Castle biosciences announces publication demonstrating dermatologists are increasingly integrating decisiondx-melanoma into melanoma clinical management decisions 03/25/2021
Castle biosciences announces fourth quarter and full-year 2020 results 03/08/2021
Castle biosciences to release fourth quarter and full year 2020 financial results and host conference call on monday, march 8, 2021 02/22/2021
Castle biosciences to present at upcoming investor conferences 02/08/2021
Castle biosciences presents new data on the validity and accuracy of decisiondx-melanoma in patients with t1 cutaneous melanoma tumors at the 19th annual south beach symposium 02/04/2021
Castle biosciences to present data on decisiondx®-melanoma, decisiondx® diffdx™-melanoma at 18th annual winter clinical dermatology conference 01/20/2021
Castle biosciences announces preliminary fourth quarter and full-year 2020 results 01/13/2021
Castle biosciences to present at the 23rd annual needham virtual growth conference 01/04/2021
Castle biosciences announces early repayment of debt 12/22/2020
Castle biosciences announces closing of public offering of common stock and full exercise of underwriters' option to purchase additional shares 12/18/2020
Castle biosciences announces pricing of $232 million public offering of common stock 12/15/2020
Castle biosciences announces commencement of proposed public offering of common stock 12/14/2020
Castle biosciences announces publication of peer-reviewed publication demonstrating the clinical impact of decisiondx®-melanoma 12/04/2020
Castle biosciences to participate in piper sandler 32nd annual virtual healthcare conference 11/23/2020
Castle biosciences announces publication of clinical validation and utility data for decisiondx® diffdx™-melanoma for suspicious pigmented lesions 11/17/2020
Castle biosciences presents data on decisiondx®-melanoma and decisiondx® diffdx™-melanoma tests at american society of dermatopathology (asdp) 57th virtual annual meeting 11/12/2020
Castle biosciences announces commercial launch of decisiondx diffdx-melanoma 11/02/2020
Castle biosciences to hold webcast for investors highlighting commercial launch of confirmdx®-melanoma 10/21/2020
Melanoma research alliance announces 13 dermatology fellowship awards 10/08/2020
Trisalus life sciences lays out therapeutic strategy upon acquisition of first therapeutic candidate 09/24/2020
Europe melanoma market and competitive landscape report 2020: pipeline, epidemiology, market valuations, drug sales, market forecast, drug forecasts, & market shares 2016-2024 - researchandmarkets.com 09/22/2020
Apple app store approves everbridge’s next-gen covid-19 contact tracing software solution amid continued global adoption by education, retail, hospital and government sectors 09/14/2020
Castle biosciences to hold webcast highlighting commercial launch of decisiondx-scc 08/26/2020
Castle biosciences posts q2 loss per share of $0.08 08/10/2020
Castle biosciences to release second quarter 2020 financial results and host conference call on monday, august 10, 2020 07/27/2020
Castle biosciences to release second quarter 2020 financial results and host conference call on monday, august 10, 2020 07/27/2020
Castle biosciences announces publication of clinical utility, long-term outcomes data and meta-analysis for decisiondx-um for patients with uveal melanoma 07/15/2020
Castle biosciences announces full exercise of underwriters’ option to purchase additional shares of common stock 07/02/2020
Castle biosciences announces pricing of $74 mln public offering of stock 06/25/2020
Castle biosciences announces pricing of $74.0 million public offering of common stock 06/25/2020
Castle biosciences announces proposed underwritten public offering of common stock 06/22/2020
Castle biosciences announces proposed underwritten public offering of common stock 06/22/2020
New data demonstrates significant and risk-appropriate clinical impact of decisiondx-scc test results on patient management decisions 05/19/2020
Global melanoma markets, pipeline, epidemiology, competitive analysis, drug sales and shares (2016-2024) - researchandmarkets.com 05/12/2020
Castle biosciences announces first quarter 2020 results 05/11/2020
Castle biosciences to release first quarter 2020 financial results and host conference call on monday, may 11, 2020 04/27/2020
Castle biosciences forecasts fy2020 revenue between $61 million and $64 million 03/10/2020
Castle biosciences to release fourth quarter and full year 2019 financial results and host conference call on tuesday, march 10, 2020 02/25/2020
Derek j. maetzold reported a passive stake of 11.3% in castle biosciences as of dec 31, 2019 - sec filing 02/12/2020
Castle biosciences announces preliminary q4 and fy 2019 performance results 01/09/2020
Castle biosciences presents expanded data supporting use of decisiondx-melanoma test to inform sentinel lymph node biopsy recommendations 11/24/2019
Castle biosciences, inc. presents at piper jaffray 31st annual healthcare conference, dec-04-2019 02:30 pm 11/19/2019
Castle biosciences reports q3 revenue $14.8 million versus $3.7 million 11/11/2019
Castle biosciences, inc. reports earnings results for the third quarter ended september 30, 2019 11/10/2019
Castle biosciences, inc. to report q3, 2019 results on nov 11, 2019 11/01/2019
Castle biosciences, inc. presents clinical validation study for its cutaneous squamous cell carcinoma prognostic test at the american society for dermatologic surgery (asds) 2019 annual meeting 10/28/2019
Castle biosciences to release third quarter 2019 financial results and host conference call on monday, november 11, 2019 10/28/2019
Castle biosciences, inc., q3 2019 earnings call, nov 11, 2019 10/27/2019
Castle biosciences presents data at the asdp 56th annual meeting supporting decisiondx-melanoma test’s ability to identify t1 melanoma patients at low risk for a positive sentinel lymph node 10/17/2019
Castle biosciences to release second quarter 2019 financial results and host conference call on tuesday, september 3, 2019 08/22/2019

More Headlines

News
Castle Biosciences to Participate in Upcoming Investor Conferences FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CastleBiosciences--Castle Biosciences today announced that Derek Maetzold and Frank Stokes will present a company overview at Baird's 2023 Global Healthcare Conference. 09/05/2023
Why Castle Biosciences Stock Is Jumping Today Castle reported stronger Q2 revenue growth and a lower net loss than analysts anticipated. The company also raised its full-year revenue outlook. 08/03/2023
Here's What Key Metrics Tell Us About Castle Biosciences, Inc. (CSTL) Q2 Earnings While the top- and bottom-line numbers for Castle Biosciences, Inc. (CSTL) give a sense of how the business performed in the quarter ended June 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values. 08/02/2023
Earnings Preview: Castle Biosciences, Inc. (CSTL) Q2 Earnings Expected to Decline Castle Biosciences, Inc. (CSTL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. 07/26/2023
Castle Biosciences to Release Second Quarter 2023 Financial Results and Host Conference Call on Wednesday, Aug. 2 FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CSTL--Castle will release its financial results for the second quarter and six months ended June 30, 2023, after the close of market on Aug. 2, 2023. 07/19/2023
Why Shares of Castle Biosciences Fell This Week Castle's CEO and board chairman each unloaded significant amounts of company stock. The company focuses on medical diagnostic tests, primarily to inform cancer treatment choices. 07/13/2023
Castle Biosciences stock soars on Medicare reversal; data presentation Castle Biosciences, Inc shares surged 55% to $20.64 on Friday after Novitas, a regional Medicare administrative contractor, reversed its draft policy that would have denied coverage of Castle's DecisionDx cancer tests for squamous cell carcinoma (SCC) and melanoma. Novitas stated that its original local coverage determination (LCD) was scheduled to go into effect on July 17, 2023, and now plans to create a new draft LCD for Castle's DecisionDx tests. 07/07/2023
Why Castle Biosciences Stock Is Crushing It Today Novitas is withdrawing a draft policy that would have denied coverage for Castle's cancer tests. It must still wait on a new draft policy from the regional Medicare administrative contractor. 07/07/2023
Castle Biosciences to Present New DecisionDx®-SCC and DecisionDx®-Melanoma Data at the American Head & Neck Society's (AHNS) 11th International Conference on Head and Neck Cancer FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CSTL--Castle will present new data on DecisionDx®-SCC and DecisionDx®-Melanoma at AHNS' 11th International Conference on Head and Neck Cancer. 07/07/2023
Why Shares of Castle Biosciences Plummeted on Monday A Medicare contractor proposed non-coverage of one of Castle's skin cancer tests. The company reiterated guidance. 06/05/2023
Why Shares of Castle Biosciences Slumped This Week Castle Biosciences' shares are down more than 3% this year. The company specializes in medical diagnostics to improve patient treatment plans. 06/02/2023
Castle Biosciences, Inc. (CSTL) Q1 2023 Earnings Call Transcript Castle Biosciences, Inc. (NASDAQ:CSTL ) Q1 2023 Earnings Conference Call May 3, 2023 4:30 PM ET Company Participants Camilla Zuckero - Vice President, Investor Relations & Corporate Affairs Derek Maetzold - Founder, President & Chief Executive Officer Frank Stokes - Chief Financial Officer Conference Call Participants Thomas Flaten - Lake Street Capital Markets Puneet Souda - SVB Catherine Schulte - Baird Mark Massaro - BTIG Sung Ji Nam - Scotiabank Operator Good afternoon, and welcome to Castle Biosciences First Quarter 2023 Conference Call. As a reminder, today's call is being recorded. 05/03/2023
7 Value Stocks to Buy for Long-Term Growth For investors that have the patience to ride out volatility in exchange for possible long-term upside, value stocks to buy that are discounted against book value may offer considerable intrigue. On paper, book value represents the difference between the company's total assets and total liabilities. 03/26/2023
Castle Biosciences to Present at the KeyBanc Capital Markets Virtual Life Sciences & MedTech Investor Forum FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CSTL--Castle will present a company overview at the KeyBanc Capital Markets Virtual Life Sciences & MedTech Investor Forum on March 22 at 2:15 p.m. Eastern. 03/14/2023
Castle Biosciences, Inc. (CSTL) Q4 2022 Earnings Call Transcript Castle Biosciences, Inc. (NASDAQ:CSTL ) Q4 2022 Earnings Conference Call February 28, 2023 4:30 PM ET Company Participants Camilla Zuckero - Vice President, Investor Relations and Corporate Affairs Derek Maetzold - Founder, President and Chief Executive Officer Frank Stokes - Chief Financial Officer Conference Call Participants Sung Ji Nam - Scotiabank Thomas Flaten - Lake Street Operator Good afternoon, and welcome to Castle Biosciences Fourth Quarter 2022 Conference Call. As a reminder, today's call is being recorded. 03/03/2023
Castle Biosciences, Inc. (CSTL) Reports Q4 Loss, Tops Revenue Estimates Castle Biosciences, Inc. (CSTL) delivered earnings and revenue surprises of 14.29% and 4.96%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock? 02/28/2023
Castle Biosciences to Release Fourth Quarter and Full-Year 2022 Financial Results and Host Conference Call on Tuesday, Feb. 28, 2023 FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CSTL--Castle will release its financial results for the fourth quarter and year ended Dec. 31, 2022, after the close of market on Tuesday, Feb. 28, 2023. 02/07/2023
Castle Biosciences: Potential To Re-Rate With Supportive Fundamentals, Technicals, Underlying Market Castle Biosciences has niche exposure to skin cancer, offering uncorrelated alpha potential. The stock is beaten down, with a chance to re-rate to the upside. 12/15/2022
Castle Biosciences, Inc. (CSTL) Q3 2022 Earnings Call Transcript Castle Biosciences, Inc. (NASDAQ:CSTL ) Q3 2022 Earnings Conference Call November 2, 2022 4:30 PM ET Company Participants Camilla Zuckero - Vice President, Investor Relations and Corporate Affairs Derek Maetzold - Founder, President and Chief Executive Officer Frank Stokes - Chief Financial Officer Conference Call Participants Catherine Schulte - Baird Puneet Souda - SVB Securities Thomas Flaten - Lake Street Mark Massaro - BTIG Mason Carrico - Stephens, Inc Operator Good afternoon and welcome to Castle Biosciences Third Quarter 2022 Conference Call. [Operator Instructions] I would like to turn the call over to Camilla Zuckero, Vice President, Investor Relations and Corporate Affairs. 11/03/2022
Castle Biosciences Presents New Data Demonstrating the Impact of DecisionDx®-SCC Test Results on the Management of Medicare-Eligible Patients with Cutaneous Squamous Cell Carcinoma and One or More Risk Factors FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CSTL--Castle announced new data showing that DecisionDx-SCC test results positively impacted patient management in over 80% of a Medicare-eligible cohort. 10/24/2022
Castle Biosciences to Present Data Supporting the Clinical Value of Its Suite of Skin Cancer Tests through Multiple Oral Presentations at the 2022 American Society for Dermatologic Surgery (ASDS) Annual Meeting FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CSTL--Castle will present data highlighting its portfolio of skin cancer GEP tests at the 2022 ASDS Annual Meeting. 10/10/2022
Castle Biosciences to Participate in Upcoming Investor Conferences FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CSTL--Castle Biosciences is scheduled to present a company overview at Baird's 2022 Global Healthcare Conference on Tuesday, Sept. 13, 2022, at 2 p.m. ET. 09/01/2022
Castle Biosciences, Inc. (CSTL) CEO Derek Maetzold on Q2 2022 Results - Earnings Call Transcript Castle Biosciences, Inc. (NASDAQ:CSTL ) Q2 2022 Earnings Conference Call August 8, 2022 4:30 PM ET Company Participants Camilla Zuckero - Executive Director of IR & Corporate Communications Derek Maetzold - Founder, President & CEO Frank Stokes - CFO Conference Call Participants Mason Carrico - Stephens Tom Peterson - Baird Puneet Souda - SVB Leerink Operator Good afternoon, and welcome to the Castle Biosciences Second Quarter 2022 Conference Call. As a reminder, today's call is being recorded. 08/12/2022
Castle Biosciences, Inc. (CSTL) Reports Q2 Loss, Tops Revenue Estimates Castle Biosciences, Inc. (CSTL) delivered earnings and revenue surprises of 89.66% and 22.67%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock? 08/08/2022
Castle Biosciences to Present at the Canaccord Genuity 42nd Annual Growth Conference FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CSTL--Castle will present a company overview at the Canaccord Genuity 42nd Annual Growth Conference on Wednesday, Aug. 10, 2022, at 1:00 p.m. Eastern time 08/03/2022
Earnings Preview: Castle Biosciences, Inc. (CSTL) Q2 Earnings Expected to Decline Castle Biosciences, Inc. (CSTL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. 08/01/2022
Castle Biosciences to Release Second Quarter 2022 Financial Results and Host Conference Call on Monday, August 8 FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CSTL--Castle will release its financial results for the second quarter and six months ended June 30, 2022, on Monday, Aug. 8, 2022. 07/25/2022
7 Micro-Cap Stocks to Buy and Hold for the Next 10 Years Finding micro-cap stocks to buy requires a bit of everything, including patience. Today's plan is to pick from the top of the IWC ETF. 05/11/2022
Castle Biosciences, Inc. (CSTL) CEO Derek Maetzold on Q1 2022 Results - Earnings Call Transcript Castle Biosciences, Inc. (NASDAQ:CSTL ) Q1 2022 Results Conference Call May 9, 2022 4:30 PM ET Company Participants Camilla Zuckero - Executive Director of Investor Relations and Corporate Communications Derek Maetzold - Founder, President and Chief Executive Officer Frank Stokes - Chief Financial Officer Conference Call Participants Puneet Souda - SVB Leerink Catherine Schulte - Baird Mason Carrico - Stephens Thomas Flaten - Lake Street Capital Markets Kyle Mikson - Canaccord Mark Massaro - BTIG Operator Good afternoon, and welcome to Castle Biosciences First Quarter 2022 Conference Call. As a reminder, today's call is being recorded. 05/09/2022
Castle Biosciences, Inc. (CSTL) Reports Q1 Loss, Tops Revenue Estimates Castle Biosciences, Inc. (CSTL) delivered earnings and revenue surprises of -19.40% and 6.87%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock? 05/09/2022
Castle Biosciences to Release First Quarter 2022 Financial Results and Host Conference Call on Monday, May 9 FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CSTL--Castle Biosciences will release its financial results for the first quarter ended March 31, 2022, after the close of market on Monday, May 9, 2022. 04/25/2022
Castle Biosciences to Present Data at the 18th European Association of Dermato Oncology (EADO) Congress FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CSTL--Castle will present data on its skin cancer gene expression profile tests at the 18th European Association of Dermato Oncology (EADO) Congress. 04/20/2022
Castle Biosciences to Present at the 21st Annual Needham Virtual Healthcare Conference FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CSTL--Castle Biosciences will present a company overview at the 21st Annual Needham Virtual Healthcare Conference on April 12, 2022, at 3:00 p.m. ET. 04/05/2022
Castle Biosciences, Inc.'s (CSTL) CEO Derek Maetzold on Q4 2021 Results - Earnings Call Transcript Castle Biosciences, Inc.'s (CSTL) CEO Derek Maetzold on Q4 2021 Results - Earnings Call Transcript 02/28/2022
Castle Biosciences, Inc. (CSTL) Reports Q4 Loss, Tops Revenue Estimates Castle Biosciences, Inc. (CSTL) delivered earnings and revenue surprises of 41.86% and 6.89%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock? 02/28/2022
Castle Biosciences to Release Fourth Quarter and Full-Year 2021 Financial Results and Host Conference Call on Monday, Feb. 28, 2022 FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CSTL--Castle will release its financial results for the fourth quarter and year-ended Dec. 31, 2021, after the close of market on Monday, Feb. 28, 2022. 02/14/2022
Castle Biosciences to Present at the 24th Annual Needham Growth Conference FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CSTL--Castle Biosciences is scheduled to present a company overview at the 24th Annual Needham Growth Conference, Jan. 10, 2022, at 12:30 p.m. Eastern time. 12/28/2021
What's Next For Castle Biosciences Stock? The stock price of Castle Biosciences (NASDAQ: CSTL), a skin cancer diagnostic company, has seen a fall of over 9% last month, while it is down 12% in a week. The recent fall can be attributed to its downbeat Q3 results. 11/11/2021
Castle Biosciences, Inc. (CSTL) CEO Derek Maetzold on Q3 2021 Results - Earnings Call Transcript Castle Biosciences, Inc. (CSTL) CEO Derek Maetzold on Q3 2021 Results - Earnings Call Transcript 11/08/2021
Castle Biosciences to Release Third Quarter 2021 Financial Results and Host Conference Call on Monday, Nov. 8, 2021 FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #DecisionDxMelanoma--Castle will release its financial results for the third quarter and nine months ended Sept. 30, 2021, after the close of market on Nov. 8, 2021. 10/25/2021
Castle Biosciences Awarded U.S. Federal Supply Schedule Contract for DecisionDx-Melanoma FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CSTL--Castle announced that it has been awarded a five-year U.S. Federal Supply Schedule (FSS) contract for its DecisionDx®-Melanoma test. 08/24/2021
Castle Biosciences, Inc (CSTL) CEO Derek Maetzold on Q2 2021 Results - Earnings Call Transcript Castle Biosciences, Inc (CSTL) CEO Derek Maetzold on Q2 2021 Results - Earnings Call Transcript 08/11/2021
Castle Biosciences Q2 Earnings Edges Out Expectation On Record Test Report Volume After the market close on Monday, Castle Biosciences Inc (NASDAQ: CSTL) reported that its second-quarter revenues rose 79% Y/Y to $22.75 million, beating the consensus of $18.93 million. The increase was attributable to more than double the number of tests delivered during the quarter. 08/10/2021
Castle Biosciences, Inc. (CSTL) Reports Q2 Loss, Tops Revenue Estimates Castle Biosciences, Inc. (CSTL) delivered earnings and revenue surprises of -17.24% and 19.21%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock? 08/09/2021
Castle Biosciences to Present Data at the 2021 American Academy of Dermatology (AAD) Summer Meeting FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #DecisionDxMelanoma--Castle Biosciences announced oral data presentations on two of its skin cancer gene expression profile tests during the 2021 AAD Summer Meeting. 08/06/2021
Analysts Estimate Castle Biosciences, Inc. (CSTL) to Report a Decline in Earnings: What to Look Out for Castle Biosciences, Inc. (CSTL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. 08/02/2021
Castle Biosciences Collaborates with the Melanoma Research Foundation FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #DecisionDxMelanoma--Castle today announced its continued collaboration with the Melanoma Research Foundation (MRF). 08/02/2021
Castle Biosciences to Release Second Quarter 2021 Financial Results and Host Conference Call on Monday, Aug. 9, 2021 FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #castlebiosciences--Castle Biosciences announced that it will release its financial results for the second quarter and six months ended June 30, 2021 on Aug. 9, 2021. 07/26/2021
Castle Biosciences Presents Data on DecisionDx®-Melanoma and DecisionDx®-SCC at SDPA Annual Summer Dermatology Conference 2021 FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #SDPA--Castle Biosciences announced data presentations at the Society of Dermatology Physician Assistants (SDPA) Annual Summer Dermatology Conference 2021. 07/22/2021
Castle Biosciences Expands its Board of Directors with New Appointments FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #boardofdirectors--Castle announced that Kim Caple and Ellen Goldberg have been appointed to its board of directors, effective immediately. 07/16/2021
AltheaDx, Inc. appoints industry veteran Derek Maetzold to its Board of Directors SAN DIEGO, May 26, 2021 /PRNewswire/ -- AltheaDx, a commercial stage, precision medicine company with the world's leading pharmacogenomics test for anxiety and depression announced today that it has appointed Derek Maetzold to its Board of Directors. Mr. Maetzold is AltheaDx's fourth Director and brings not only strong knowledge of the diagnostics industry, but also operations and management experience. 05/26/2021
Castle Biosciences Supports the American Skin Association with Research Grant FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #AmericanSkinAssociation--Castle today announced its collaboration with the American Skin Association to provide a 2021 research grant in the area of melanoma. 05/21/2021
Castle Biosciences, Inc (CSTL) CEO Derek Maetzold on Q1 2021 Results - Earnings Call Transcript Castle Biosciences, Inc (CSTL) CEO Derek Maetzold on Q1 2021 Results - Earnings Call Transcript 05/10/2021
Castle Biosciences, Inc. (CSTL) Reports Q1 Loss, Tops Revenue Estimates Castle Biosciences, Inc. (CSTL) delivered earnings and revenue surprises of 22.73% and 33.14%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock? 05/10/2021
Castle Biosciences: Q1 Earnings Insights Shares of Castle Biosciences (NASDAQ:CSTL) were unchanged in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share decreased 666.67% over the past year to ($0.17), which beat the estimate of ($0.24). 05/10/2021
Castle Biosciences Announces First Quarter 2021 Results FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #castlebiosciences--Castle today announced its financial results for the first quarter ended March 31, 2021. 05/10/2021
Analysts Estimate Castle Biosciences, Inc. (CSTL) to Report a Decline in Earnings: What to Look Out for Castle Biosciences, Inc. (CSTL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. 05/03/2021
Castle Biosciences Signs Definitive Agreement to Acquire Myriad myPath® Laboratory FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #DiffDxMelanoma--Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today announced it has signed a definitive agreement to acquire all of the equity of Myriad myPath, LLC (Myriad myPath Laboratory), from Myriad Genetics. Myriad myPath Laboratory is a CLIA-certified laboratory in Salt Lake City, where the myPath Melanoma 23-gene expression profile (GEP) test was develope 04/27/2021
Castle Biosciences Presents Data at the 10th World Congress of Melanoma and 17th European Association of Dermato-Oncology Congress FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #10thWCM--Castle presented data on its three skin cancer gene expression profile tests at the 10th World Congress of Melanoma. 04/16/2021
Castle Biosciences Announces Prospective, Multi-Center Publication Demonstrating DecisionDx®-Melanoma as Significant, Independent Predictor of Patient Outcomes in Cutaneous Melanoma FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #Melanoma--Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today announced the publication of prospective, multi-center long-term outcomes data in cutaneous melanoma as impacted by DecisionDx®-Melanoma. DecisionDx-Melanoma is Castle's gene expression profile test that uses an individual patient's tumor biology to predict risk of cutaneous melanoma metastasis or 04/13/2021
Castle Biosciences Collaborates with the Melanoma Research Foundation for “Ask the Expert” Live Webinar Series with Melanoma Experts FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CastleBiosciences--Castle announced it will collaborate with the Melanoma Research Foundation (MRF) to present “Ask the Expert” Managing Melanoma, a webinar series. 04/01/2021
Castle Biosciences to Present at the 20th Annual Needham Virtual Healthcare Conference FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CastleBiosciences--Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today announced that Derek Maetzold, president and chief executive officer, is scheduled to present a company overview at the 20th Annual Needham Virtual Healthcare Conference on April 12, 2021, at 4:30 p.m. Eastern time. A live audio webcast of the company's presentation will be available by visiting Ca 03/29/2021
Castle Biosciences Announces Publication Demonstrating Dermatologists Are Increasingly Integrating DecisionDx-Melanoma Into Melanoma Clinical Management Decisions FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #DecisionDxMelanoma--Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today announced the publication of a cross-sectional study of dermatologists that found its respondents are increasingly incorporating DecisionDx®-Melanoma into the management of their patients with melanoma. DecisionDx-Melanoma is Castle's gene expression profile test that uses an individual patient's t 03/25/2021
Can Castle Biosciences Stock Rebound After The Recent 24% Drop? The stock price of Castle Biosciences, a skin cancer diagnostic company, has seen a large 24% drop over the last ten trading days, while it is down 14% over the last five trading days. We believe the stock, after the recent drop, may trend higher in the near term. 03/12/2021
Castle Biosciences, Inc. (CSTL) Moves 5.3% Higher: Will This Strength Last? Castle Biosciences, Inc. (CSTL) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term. 03/11/2021
Castle Biosciences, Inc (CSTL) CEO Derek Maetzold on Q4 2020 Results - Earnings Call Transcript Castle Biosciences, Inc (CSTL) CEO Derek Maetzold on Q4 2020 Results - Earnings Call Transcript 03/08/2021
Castle Biosciences, Inc. (CSTL) Reports Q4 Loss, Tops Revenue Estimates Castle Biosciences, Inc. (CSTL) delivered earnings and revenue surprises of -45.45% and 10.62%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock? 03/08/2021
Castle Biosciences Announces Fourth Quarter and Full-Year 2020 Results FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CastleBiosciences--Castle Biosciences Announces Fourth Quarter and Full-Year 2020 Results 03/08/2021
Is a Surprise Coming for Castle Biosciences (CSTL) This Earnings Season? Castle Biosciences (CSTL) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season. 03/05/2021
Castle Biosciences, Inc. (CSTL) Expected to Beat Earnings Estimates: Can the Stock Move Higher? Castle Biosciences, Inc. (CSTL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. 03/01/2021
Castle Biosciences to Release Fourth Quarter and Full Year 2020 Financial Results and Host Conference Call on Monday, March 8, 2021 FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #SkinCancer--Castle will release its financial results for the fourth quarter and year-ended December 31, 2020, after the close of market on Monday, March 8, 2021. 02/22/2021
Castle Biosciences to Present at Upcoming Investor Conferences FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CastleBiosciences--Castle Biosciences is scheduled to present a company overview at upcoming investor conferences. 02/08/2021
Castle Biosciences Presents New Data on the Validity and Accuracy of DecisionDx-Melanoma in Patients With T1 Cutaneous Melanoma Tumors at the 19th Annual South Beach Symposium FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CastleBiosciences--Castle today announced virtual posters on its three skin cancer gene expression profile tests at the 19th Annual South Beach Symposium. 02/04/2021
Castle Biosciences to Present Data on DecisionDx®-Melanoma, DecisionDx® DiffDx™-Melanoma at 18th Annual Winter Clinical Dermatology Conference FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #DecisionDxMelanoma--Castle Biosciences to Present Data on DecisionDx®-Melanoma, DecisionDx® DiffDx™-Melanoma at 18th Annual Winter Clinical Dermatology Conference. 01/20/2021
Castle Biosciences Announces Preliminary Fourth Quarter and Full-Year 2020 Results FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #Castle--Castle today announced certain unaudited preliminary performance results for the fourth quarter and full-year 2020. 01/13/2021
Castle Biosciences to Present at the 23rd Annual Needham Virtual Growth Conference FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CSTL--Castle is scheduled to present a company overview at the 23rd Annual Needham Virtual Growth Conference on Jan. 15, 2021. 01/04/2021
Castle Biosciences Announces Early Repayment of Debt FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #skincancer--Castle today announced it prepaid in full its outstanding term loan facility. 12/22/2020
Castle Biosciences Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL--Castle Biosciences today announced the closing of its previously announced underwritten public offering. 12/18/2020
Castle Biosciences Announces Pricing of $232 Million Public Offering of Common Stock FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL--Castle Biosciences announced today the pricing of its underwritten public offering. 12/15/2020
Castle Biosciences Announces Commencement of Proposed Public Offering of Common Stock FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL--Castle announced today that it has commenced a proposed underwritten public offering. 12/14/2020
Castle Biosciences Announces Publication of Peer-Reviewed Publication Demonstrating the Clinical Impact of DecisionDx®-Melanoma FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #castlebiosciences--Castle Biosciences Announces Publication of Peer-Reviewed Publication Demonstrating the Clinical Impact of DecisionDx®-Melanoma 12/04/2020
Castle Biosciences to Participate in Piper Sandler 32nd Annual Virtual Healthcare Conference FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #cancerdiagnostics--Castle Biosciences to Participate in Piper Sandler 32nd Annual Virtual Healthcare Conference 11/23/2020
Castle Biosciences Announces Publication of Clinical Validation and Utility Data for DecisionDx® DiffDx™-Melanoma for Suspicious Pigmented Lesions FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #castlebiosciences--Castle Biosciences Announces Publication of Clinical Validation and Utility Data for DecisionDx® DiffDx™-Melanoma for Suspicious Pigmented Lesions. 11/17/2020
Castle Biosciences, Inc. (CSTL) CEO Derek Maetzold on Q3 2020 Results - Earnings Call Transcript Castle Biosciences, Inc. (CSTL) CEO Derek Maetzold on Q3 2020 Results - Earnings Call Transcript 11/09/2020
Melanoma Research Alliance Announces 13 Dermatology Fellowship Awards The Melanoma Research Alliance, the largest non-profit funder of melanoma research, has named 13 promising clinicians/researchers-in-training as 2020 10/08/2020
Melanoma Therapeutics Market Size, Analysis Top Countries In-depth Research, Trends, Emerging Growth Factors and Regional Forecasts to 2026 Oct 01, 2020 (The Expresswire) -- “Melanoma Therapeutics Market" report provides a detailed evaluation of the market by highlighting information on different... 10/01/2020
Melanoma Therapeutics Market 2020 Share, Size, Regional Trend, Future Growth, Leading Players Updates, Industry Demand, Current and Future Plans by Forecast to 2026 Oct 01, 2020 (The Expresswire) -- Global "Melanoma Therapeutics Market" 2020 report includes the market strategy, market orientation, expertise opinion and... 10/01/2020
Melanoma Therapeutics Market 2020 Share, Size, Regional Trend, Future Growth, Leading Players Updates, Industry Demand, Current and Future Plans by Forecast to 2026 Oct 01, 2020 (The Expresswire) -- Global "Melanoma Therapeutics Market" 2020 report includes the market strategy, market orientation, expertise opinion and... 10/01/2020
Melanoma Therapeutics Market 2020 Share, Size, Regional Trend, Future Growth, Leading Players Updates, Industry Demand, Current and Future Plans by Forecast to 2026 Oct 01, 2020 (The Expresswire) -- Global "Melanoma Therapeutics Market" 2020 report includes the market strategy, market orientation, expertise opinion and... 10/01/2020
TriSalus Life Sciences Lays Out Therapeutic Strategy Upon Acquisition of First Therapeutic Candidate TriSalus Life Sciences announces its therapeutic clinical development strategy following the acquisition of SD-101, from Dynavax Technologies. 09/24/2020
Europe Melanoma Market and Competitive Landscape Report 2020: Pipeline, Epidemiology, Market Valuations, Drug Sales, Market Forecast, Drug Forecasts, & Market Shares 2016-2024 - ResearchAndMarkets.com The 09/22/2020
Apple App Store Approves Everbridge’s Next-Gen COVID-19 Contact Tracing Software Solution Amid Continued Global Adoption By Education, Retail, Hospital and Government Sectors Everbridge, Inc. (NASDAQ: EVBG), the global leader in critical event management (CEM), today announced approval for the latest version of its next-gen 09/14/2020
Daniel Bradbury Sells 3,750 Shares of Castle Biosciences (NASDAQ:CSTL) Stock Castle Biosciences (NASDAQ:CSTL) Director Daniel Bradbury sold 3,750 shares of the stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $43.18, for a total value of $161,925.00. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC […] 08/22/2020
The Daily Biotech Pulse: CureVac Close To Coronavirus Vaccine Deal With EU, Entera Bio's Positive Readout, Patent Protection For Co-Diagnostics Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 19) 10X Genomics Inc (NASDAQ: TXG) ALX Oncology Holdings Inc (NASDAQ: ALXO) Avenue Therapeutics Inc (NASDAQ: ATXI)... 08/20/2020
A Closer Look At Castle Biosciences, Inc.'s (NASDAQ:CSTL) Uninspiring ROE Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is... 08/11/2020
Castle Biosciences, Inc. (CSTL) Reports Q2 Loss, Tops Revenue Estimates Castle Biosciences, Inc. (CSTL) delivered earnings and revenue surprises of 80.95% and 39.02%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock? 08/10/2020
Castle Biosciences Announces Second Quarter 2020 Results Castle Biosciences today announced its financial results for the second quarter and six months ended June 30, 2020. 08/10/2020
The Week Ahead In Biotech: Bausch Health, Fennec Pharma FDA Decisions And Smid-cap Earnings Biotech stocks advanced in the week ended Aug. 7, buoyed by multiple catalysts. Aside from the broader market strength, mostly positive earnings and continuing coronavirus... 08/09/2020
Castle Biosciences to Present at the Canaccord Genuity 40th Annual Growth Conference Castle Biosciences is scheduled to present a company overview at the Canaccord Genuity 40th Annual Growth Conference on Wednesday, August 12, 2020. 08/05/2020
Castle Biosciences, Inc. (CSTL) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release Castle Biosciences, Inc. (CSTL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. 08/03/2020
Castle Biosciences (NASDAQ:CSTL) Expected to Announce Earnings of -$0.42 Per Share Wall Street brokerages forecast that Castle Biosciences (NASDAQ:CSTL) will report earnings per share of ($0.42) for the current quarter, according to Zacks Investment Research. Two analysts have made estimates for Castle Biosciences’ earnings. The highest EPS estimate is ($0.35) and the lowest is ($0.48). Castle Biosciences posted earnings per share of ($1.05) in the same […] 08/03/2020
Castle Biosciences to Release Second Quarter 2020 Financial Results and Host Conference Call on Monday, August 10, 2020 Castle will release its financial results for the second quarter ended June 30, 2020, after the close of market on Monday, August 10, 2020. 07/27/2020
Castle Biosciences to Release Second Quarter 2020 Financial Results and Host Conference Call on Monday, August 10, 2020 Castle will release its financial results for the second quarter ended June 30, 2020, after the close of market on Monday, August 10, 2020. 07/27/2020
Castle Biosciences (NASDAQ:CSTL) Reaches New 12-Month High at $45.27 Shares of Castle Biosciences (NASDAQ:CSTL) hit a new 52-week high during trading on Wednesday . The stock traded as high as $45.27 and last traded at $44.28, with a volume of 38331 shares changing hands. The stock had previously closed at $42.97. Several equities research analysts have recently issued reports on CSTL shares. Zacks Investment […] 07/17/2020
The Daily Biotech Pulse: 2 IPOs, Nabriva Pneumonia Drug Gets Canadian Regulatory Nod, PhaseBio Doses First COVID-19 Trial Patient Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 16) AC Immune SA (NASDAQ: ACIU... 07/17/2020
Castle Biosciences Announces Publication of Clinical Utility, Long-Term Outcomes Data and Meta-Analysis for DecisionDx-UM for Patients with Uveal Melanoma Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today announced the publication of a multicenter, prospective study demonstrating that DecisionDx®-UM test results significantly impacted treatment plan recommendations for patients with uveal melanoma (UM). 07/15/2020
Castle Biosciences Announces Publication of Clinical Utility, Long-Term Outcomes Data and Meta-Analysis for DecisionDx-UM for Patients with Uveal Melanoma Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment deci 07/15/2020
Head to Head Analysis: Cancer Genetics (NASDAQ:CGIX) and Castle Biosciences (NASDAQ:CSTL) Cancer Genetics (NASDAQ:CGIX) and Castle Biosciences (NASDAQ:CSTL) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, valuation, profitability, earnings, dividends, analyst recommendations and institutional ownership. Analyst Ratings This is a breakdown of current recommendations for Cancer Genetics and Castle Biosciences, […] 07/14/2020
Second Systematic Review and Meta-Analysis Published Demonstrating DecisionDx-Melanoma as Independent Predictor of Recurrence, Distant Metastasis and Overall Survival in Cutaneous Melanoma Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today announced the publication of an independent, systematic review and meta-analysis demonstrating that its DecisionDx®-Melanoma test is a significant predictor of recurrence and metastatic risk in patients with invasive cutaneous melanoma. 07/09/2020
What Type Of Shareholders Own The Most Number of Castle Biosciences, Inc. (NASDAQ:CSTL) Shares? A look at the shareholders of Castle Biosciences, Inc. (NASDAQ:CSTL) can tell us which group is most powerful... 07/06/2020
Castle Biosciences Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares of Common Stock Castle announced the underwriters have exercised in full their option to purchase an additional 300,000 shares. 07/02/2020
Guardant Health (GH) Receives a Buy from Canaccord Genuity - Markets In a report released today, Max Masucci from Canaccord Genuity maintained a Buy rating on Guardant Health (GH – Research 07/02/2020
Castle Biosciences Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares of Common Stock Castle announced the underwriters have exercised in full their option to purchase an additional 300,000 shares. 07/02/2020
'My husband died from a cancer that is preventable' Cliona Murphy lost her husband Brendan to melanoma three years ago. Here, she talks about the difference new treatments made to extending his life, as well as the need for fundraising to continue research into further treatments. 07/01/2020
Hedge Funds Are Betting On Castle Biosciences, Inc. (CSTL) In this article we will check out the progression of hedge fund sentiment towards Castle Biosciences, Inc. (NASDAQ:CSTL) and determine whether it is a good investment right now. We at Insider Monkey like to examine what billionaires and hedge funds think of a company before spending days of research on it. Given their 2 and […] 06/26/2020
Castle Biosciences Announces Pricing of $74.0 Million Public Offering of Common Stock Castle Biosciences announced today the pricing of its underwritten public offering. 06/25/2020
Castle Biosciences Announces Pricing of $74.0 Million Public Offering of Common Stock Castle Biosciences announced today the pricing of its underwritten public offering. 06/25/2020
The Daily Biotech Pulse: Sanofi Expedites COVID-19 Vaccine Timeline, Apyx Cleared For Market Expansion, Miragen's Positive Readout The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 22) ADC Therapeutics SA (... 06/23/2020
Castle Biosciences Announces Proposed Underwritten Public Offering of Common Stock 06/22/2020
Castle Biosciences Announces Proposed Underwritten Public Offering of Common Stock Castle Biosciences has filed a registration statement on Form S-1 with the Securities and Exchange Commission (SEC). 06/22/2020
Castle Biosciences Announces Proposed Underwritten Public Offering of Common Stock Castle Biosciences has filed a registration statement on Form S-1 with the Securities and Exchange Commission (SEC). 06/22/2020
The Daily Biotech Pulse: Tiziana Snags A Patent Win, Decision Day For Nabriva And Evoke, IPOs Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 18) ADC Therapeutics SA (NYSE:... 06/19/2020
The Daily Biotech Pulse: GlaxoSmithKline, IDEAYA Strike Oncology Partnership, Decision Day For Merck, Adverum's New CEO Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 16) Applied Molecular Transport... 06/16/2020
Joseph C. Cook III Sells 2,108 Shares of Castle Biosciences (NASDAQ:CSTL) Stock Castle Biosciences (NASDAQ:CSTL) Director Joseph C. Cook III sold 2,108 shares of the business’s stock in a transaction dated Wednesday, June 10th. The shares were sold at an average price of $39.00, for a total value of $82,212.00. Following the completion of the sale, the director now directly owns 212,178 shares of the company’s stock, […] 06/14/2020
Castle Biosciences (NASDAQ:CSTL) and Anpac Bio-Medical Science (NASDAQ:ANPC) Head-To-Head Survey Castle Biosciences (NASDAQ:CSTL) and Anpac Bio-Medical Science (NASDAQ:ANPC) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, analyst recommendations, risk, dividends, earnings, institutional ownership and profitability. Insider and Institutional Ownership 42.7% of Castle Biosciences shares are owned by institutional investors. […] 06/14/2020
GenMark (GNMK) Receives a Buy from Canaccord Genuity - Markets Canaccord Genuity analyst Max Masucci maintained a Buy rating on GenMark (GNMK – Research Report) yesterday and set a price 06/11/2020
Skin cancer symptoms: The sign in your feet that could signal the deadly disease SKIN cancer symptoms most often develop on areas of the skin that have been exposed to the sun, but it can also develop on less obvious areas such as the feet. One sign of melanoma skin cancer - one of the more serious types of skin cancer - can appear on a person's toenails. 06/01/2020
Castle Biosciences Announces Change of Location of Annual Meeting of Stockholders to Be Held June 4, 2020 Castle announced a change of location of its 2020 Annual Meeting of Stockholders to The San Luis Hotel, 5222 Seawall Blvd., Galveston, TX, 77550. 05/22/2020
Castle Bisociences Grows Despite Covid19 Damping (NASDAQ:CSTL) Castle Biosciences went public in July 2019 at $16.00 per share. The firm provides a variety of diagnostic and predictive testing for skin cancers. CSTL has imp 05/21/2020
New Data Demonstrates Significant and Risk-Appropriate Clinical Impact of DecisionDx-SCC Test Results on Patient Management Decisions Castle announced publication of an intended use survey for DecisionDx®-SCC for patients diagnosed with high-risk cutaneous squamous cell carcinoma. 05/19/2020
New Data Demonstrates Significant and Risk-Appropriate Clinical Impact of DecisionDx-SCC Test Results on Patient Management Decisions Castle announced publication of an intended use survey for DecisionDx®-SCC for patients diagnosed with high-risk cutaneous squamous cell carcinoma. 05/19/2020
NYC Healthcare Heroes Expands Deliveries to 5,000 Emergency Medical Services and Disaster Services Workers NYC Healthcare Heroes is expanding the program to deliver thousands of bags of food and supplies to over 5,000 EMS and disaster services workers. 05/14/2020
Castle Biosciences Inc (CSTL) Q1 2020 Earnings Call Transcript CSTL earnings call for the period ending March 31, 2020. 05/12/2020
Global Melanoma Markets, Pipeline, Epidemiology, Competitive Analysis, Drug Sales and Shares (2016-2024) - ResearchAndMarkets.com The 05/12/2020
Castle Biosciences Announces First Quarter 2020 Results Castle today announced its financial results for the first quarter ended March 31, 2020. 05/11/2020
Castle Biosciences Announces First Quarter 2020 Results Castle today announced its financial results for the first quarter ended March 31, 2020. 05/11/2020
The Week Ahead In Biotech: Virtual Conference Presentations, Clovis PDUFA Date In The Spotlight The smid-cap biotech earnings deluge hit Wall Street in the week ended May 9, positively impacting the stocks in the sector. The iShares NASDAQ Biotechnology Index (NASDAQ: IBB)... 05/10/2020
Castle Biosciences Announces Publication of a Study Evaluating Incorporation of DecisionDx-SCC into Management of High-Risk Cutaneous Squamous Cell Carcinoma Castle announced the publication of a clinical utility model for its cutaneous squamous cell carcinoma (SCC) prognostic test, DecisionDx®-SCC. 05/05/2020
Castle Biosciences Announces Publication of Validation Study for DecisionDx-SCC, Showing this Test is an Independent Predictor of Metastatic Risk in Squamous Cell Carcinoma Castle today announced the publication of development and validation data for DecisionDx®-SCC. 04/29/2020
Castle Biosciences' Shares March Higher, Can It Continue? As of late, it has definitely been a great time to be an investor in Castle Biosciences. 04/28/2020
Castle Biosciences to Release First Quarter 2020 Financial Results and Host Conference Call on Monday, May 11, 2020 Castle Biosciences announced that it will release its financial results for the first quarter 2020, after the close of market on Monday, May 11, 2020. 04/27/2020
Stocks To Watch: Big Banks And Vaccine Players In The Spotlight Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive th 04/11/2020
Castle Biosciences to Present at the 19th Annual Needham Virtual Healthcare Conference Castle is scheduled to present at the 19th Annual Needham Virtual Healthcare Conference on Wednesday, April 15, 2020, at 3:30 p.m. Eastern. 04/06/2020
Castle Biosciences Appoints Miles Harrison to Board of Directors Castle today announced that Miles Harrison has been appointed to the board of directors, effective immediately. 04/02/2020
Castle Biosciences Announces Publication of a Systematic Review and Meta-Analysis Demonstrating DecisionDx-Melanoma Test as Independent, Significant Predictor of Recurrence and Metastatic Risk Castle announced the publication of a systematic review and meta-analysis in JAAD. 04/01/2020
Castle Biosciences Posts Results of Collaborative Ocular Oncology Group Survey on the Management of Ocular Oncology Patients During the COVID-19 Pandemic Castle Posts Results of Collaborative Ocular Oncology Group Survey on the Management of Ocular Oncology Patients During the COVID-19 Pandemic. 03/27/2020
Castle Biosciences Announces Publication of Fourth Study Demonstrating Significant Impact of DecisionDx-UM on Treatment Plan Recommendations for Patients with Uveal Melanoma Castle Announces Publication of Fourth Study Demonstrating Significant Impact of DecisionDx-UM on Treatment Plan Recommendations. 03/26/2020
Head to Head Analysis: Castle Biosciences (NASDAQ:CSTL) and Guardant Health (NASDAQ:GH) Castle Biosciences (NASDAQ:CSTL) and Guardant Health (NASDAQ:GH) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, earnings, profitability, institutional ownership, valuation and analyst recommendations. Earnings and Valuation This table compares Castle Biosciences and Guardant Health’s top-line revenue, earnings per share […] 03/22/2020
Critical Contrast: Castle Biosciences (NASDAQ:CSTL) versus Guardant Health (NASDAQ:GH) Castle Biosciences (NASDAQ:CSTL) and Guardant Health (NASDAQ:GH) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, dividends, analyst recommendations, valuation, risk and profitability. Profitability This table compares Castle Biosciences and Guardant Health’s net margins, return on equity and return […] 03/20/2020
Castle Biosciences Announces Fourth Quarter and Full-Year 2019 Results Castle announced its financial results for the fourth quarter and twelve months ended December 31, 2019. 03/10/2020
Castle Biosciences Inc to Host Earnings Call NEW YORK, NY / ACCESSWIRE / March 10, 2020 / Castle Biosciences Inc (NASDAQ:CSTL) will be discussing their earnings results in their 2019 Fourth Quarter Earnings call to be held on March 10, 2020 at 4:30 ... 03/10/2020
The Daily Biotech Pulse: Mesoblast To Test Candidate On Coronavirus Symptoms, Proxy Battle Ahead For Rockwell Medical, Glaukos to Join S&P SmallCap 600 Index Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs March 9.) Arcutis... 03/10/2020
The Daily Biotech Pulse: Trevana Pain Drug Resubmission Accepted For Review, Can-Fite To Explore Treatment For COVID-19 Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 4) * 89bio Inc (NASDAQ: ETNB) * Arcus Biosciences Inc (NYSE: RCUS) * Arcturus Therapeutics Ltd (NASDAQ: ARCT)(announced a partnership with Duke-NUS 03/05/2020
Castle Biosciences Announces Issuance of First U.S. Patent Covering DecisionDx-Melanoma Castle was issued its first U.S. patent related to DecisionDx-Melanoma. 03/05/2020
Netflix And Dow Heavyweights Into The Earnings Confessional Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive th 01/18/2020
Houston-area biotech co. to hire, double office space after $73.6M IPO Friendswood-based Castle Biosciences Inc. (Nasdaq: CSTL) has growth in mind after closing a multimillion-dollar initial public offering in 2019. Derek Maetzold, founder, president and CEO of Castle Biosciences, told the Houston Business Journal that the company will more than double its current office space when Castle moves later this year. Castle will occupy 21,760 square feet at 505 S. Friendswood Drive — a new building a little over half a mile away from the company's current digs at 820 S. Friendswood — by late in the second quarter or early Q3, Maetzold said. 01/14/2020
Does Castle Biosciences (NASDAQ:CSTL) Have A Healthy Balance Sheet? Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility... 12/24/2019
We reveal 4 reasons your sun cream might not be working, causing you to burn IT’S summer in Britain and with the heatwave comes the inevitable rainbow of sunburn. With health bods ramming home the importance of sun cream there really is no excuse. Or is there? We all … 06/23/2017
Skin Analytics Seeks Funds on Crowdcube to Battle Melanoma Using Smartphone App & Attachable Camera Hoping to put an end to mortality rate for Melanoma, Skin Analytics has launched an equity crowdfunding campaign on Crowdcube to raise £450,000 for its new ear 10/15/2015
Castle Biosciences Closes $11.7M Tranche of $20M Series F Financing Castle Biosciences, Inc., a provider of molecular diagnostics to improve cancer treatment decisions, today announced it has closed the first tranche of a $20 mi 07/27/2015

Unlock

CSTL Ratings Summary

CSTL Quant Ranking